Efficacy of rituximab in refractory neuromyelitis optica

Multiple Sclerosis

Volumn 22, Issue 7, 2016, Pages 955-959

  Collongues, N ^a   Brassat, D ^b   Maillart, E ^c   Labauge, P ^d   Ouallet, J C ^e   Carra Dalliere, C ^d   Moreau, T ^f   Bourre, B ^g   Papeix, C ^c   Brochet, B ^e   Audoin, B ^h   Vukusic, S ⁱ   De Seze, J ^a   Marignier, R ⁱ  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b CHU PURPAN   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f DIJON UNIVERSITY HOSPITAL   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h AIX MARSEILLE UNIVERSITY   (France)

ⁱ HÔPITAL NEUROLOGIQUE   (France)

Author keywords

body mass index; disability; Neuromyelitis optica; refractory; rituximab

Indexed keywords

RITUXIMAB; AQUAPORIN 4 ANTIBODY; CORTICOSTEROID; MYCOPHENOLATE MOFETIL; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MALE; MYELOOPTIC NEUROPATHY; RELAPSE; ABSENCE OF SIDE EFFECTS; AGED; COHORT ANALYSIS; DRUG INFUSION; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RATE; REFRACTORY MYELOOPTIC NEUROPATHY; ADOLESCENT; DISABILITY; DISEASE EXACERBATION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; REMISSION; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECURRENCE; REMISSION INDUCTION; RISK FACTORS; RITUXIMAB; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84973441766     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515602337     Document Type: Article

References (11)

1. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225-1230.
2. Greenberg BM, Graves D, Remington G, et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012; 18: 1022-1026.
3. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 2013; 324: 38-39.
4. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
5. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315.
6. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
7. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
8. Bichuetti DB, Oliveira EM, Boulos Fde C, et al. Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients. Archives of neurology 2012; 69: 938-939.
9. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71: 324-330.
10. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013; 81: 710-713.
11. Kim SH, Kim W, Li XF, et al. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 2011; 68: 1412-1420.